Answers are grounded in this paper and cite their sources.
Results from the ongoing LAANTERN registry demonstrate that LITT stabilizes and improves QoL from baseline levels in a malignant brain tumor patient population with high rates of comorbidities. Overall survival was better than anticipated for a real-world registry and comparative to published literature.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: